News Early Clovis approval notches up competition in ovarian canc... Clovis' Rubraca will compete against AstraZeneca rival.
News Electrical patch device shows promise against ovarian cancer Novocure's Optune device shown to be safe and tolerable in recurrent ovarian cancer.
News Clovis takes stock as rival Tesaro shines Oncology firm could make acquisition if ovarian cancer drug approved.
News Praxis soars on rare childhood epilepsy trial data Praxis looks like it could be filing for approval of two products next year, after its childhood epilepsy drug delivered a win in a pivotal trial.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
